INSTITUT CURIE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Private
- Established
- 1909-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.curie.fr
Egle Therapeutics Secures €9.3 Million in French Government Funding to Advance Treg-Targeting Cancer Therapies
• Egle Therapeutics has received €9.3 million in non-dilutive funding from France 2030's "Innovations in Biotherapies and Bioproduction" initiative to accelerate development of its lead immuno-oncology candidate EGL-001.
• The clinical-stage biotech, a 2020 spin-off from Institut Curie, has developed a proprietary platform to identify novel tumor-infiltrating regulatory T cell (Treg) targets for cancer and autoimmune disease treatments.
• Since its founding, Egle has raised nearly €56 million through equity financing and non-dilutive funding, with its lead candidate EGL-001 currently in Phase I/II clinical trials in France and Spain.
ESR1 Mutations in Breast Cancer: Emerging Biomarker Reshapes Treatment Strategies
• ESR1 mutations are rare (<5%) in newly diagnosed breast cancer but develop in 30-40% of patients after aromatase inhibitor therapy, enabling tumors to remain active without estrogen.
• Circulating tumor DNA testing for ESR1 mutations is typically performed at disease progression, but emerging research suggests earlier detection could optimize treatment decisions.
• The presence of ESR1 mutations helps guide therapy selection, with oral selective estrogen receptor degraders like elacestrant showing improved efficacy compared to standard treatments.
Greenwich LifeSciences Expands Phase III Breast Cancer Trial Globally, Adds New Sites and Expertise
• Greenwich LifeSciences broadens its Phase III FLAMINGO-01 trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence, by adding new clinical sites in the U.S. and Europe.
• The trial expands into France through a partnership with Unicancer, activating 19 sites, and collaborates with GBG in Germany, adding approximately 38 sites to the study.
• Harvard and Johns Hopkins join the trial in the U.S., with principal investigators Dr. Laura Spring and Dr. Cesar Santa-Maria joining the Steering Committee.
• EMA approves the addition of 11 sites in Spain, Germany, and Poland, potentially activating 110-115 sites in Europe, with plans to expand to Ireland, Romania, and other countries.
Distinct Mechanisms of HER2-Targeting Agents in NSCLC: Understanding TKIs vs ADCs
• TKIs target the intracellular kinase domain of HER2, inhibiting cell proliferation pathways, while ADCs utilize antibodies to deliver cytotoxic payloads directly to cancer cells.
• HER2-directed ADCs demonstrate broader efficacy across various HER2 alterations, including mutations, amplifications, and overexpression, offering versatile treatment options.
• TKIs offer advantages of oral administration and established safety profiles, though their effectiveness can vary depending on specific HER2 mutations in the ATP binding domain.
Arvinas Advances Vepdegestrant into Phase 3 Trials for Breast Cancer and Updates Pipeline Milestones
• Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
• Topline data from the Phase 3 VERITAC-2 monotherapy trial of vepdegestrant in second-line-plus ER+/HER2- metastatic breast cancer is anticipated in the first quarter of 2025.
• Arvinas is set to present initial data from the Phase 1 trial of ARV-393 in B-cell lymphomas and file an IND application for a novel PROTAC KRAS G12D degrader in 2025.
• Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease has been initiated, with data expected to be presented in the first half of 2025.
Bayer's Elinzanetant Shows Promise in Reducing Hot Flashes for Breast Cancer Patients
• Elinzanetant met primary endpoints in the Phase III OASIS 4 trial, significantly reducing the frequency of moderate to severe vasomotor symptoms (VMS) in women undergoing endocrine therapy for breast cancer.
• The study also achieved secondary endpoints, demonstrating a reduction in the severity of VMS, improvements in sleep disturbances, and enhanced menopause-related quality of life compared to placebo.
• Elinzanetant is a dual neurokinin-1 and 3 receptor antagonist, representing a potential non-hormonal treatment option for VMS in breast cancer patients and women at high risk.
• Bayer is advancing regulatory submissions for elinzanetant in the US, EU, and other global markets, with potential launch expected later this year, pending regulatory approvals.
Amivantamab Plus Lazertinib Demonstrates Superior Overall Survival in EGFR-Mutated NSCLC
• The MARIPOSA trial demonstrated that amivantamab plus lazertinib significantly improved overall survival (OS) compared to osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC).
• The combination therapy showed a 30% reduction in the risk of disease progression or death, with a median progression-free survival (PFS) of 23.7 months versus 16.6 months for osimertinib.
• Updated data from the MARIPOSA trial presented at the 2024 IASLC World Conference on Lung Cancer showed a sustained benefit in intracranial PFS with amivantamab plus lazertinib.
• Enhanced dermatologic management in the COCOON trial reduced the incidence of skin-related adverse events associated with amivantamab and lazertinib, improving patient quality of life.
Merus' Petosemtamab and Mersana's Emi-Le Show Promise in Cancer Treatment
• Merus' petosemtamab demonstrates a 36% overall response rate in recurrent/metastatic head and neck squamous cell carcinoma, with median overall survival of 11.4 months.
• Mersana Therapeutics' Emi-Le receives Fast Track designation for HER2-negative breast cancer, showing promising monotherapy activity in multiple tumors.
• Petosemtamab's clinical trials are ongoing, including phase 3 studies in HNSCC and expanded evaluation in metastatic colorectal cancer, with data updates planned for 2025.
Transgene and NEC's TG4050 Shows Sustained Disease-Free Survival in Head and Neck Cancer Trial
• TG4050, an individualized immunotherapy, demonstrates 100% disease-free survival at 24.1 months in head and neck cancer patients after standard adjuvant therapy.
• The neoantigen cancer vaccine induced immune responses targeting selected neoantigens in all treated patients, showing strong and sustained immunogenicity.
• The ongoing Phase I/II trial is expanding internationally, with Phase II currently enrolling patients to further confirm these promising findings.
• TG4050 combines Transgene's myvac platform with NEC's AI to personalize cancer treatment by stimulating the immune system against tumor-specific mutations.
Transgene and NEC's TG4050 Cancer Vaccine Shows Sustained Disease-Free Survival in Head and Neck Cancer Trial
• TG4050, an individualized immunotherapy, demonstrates a 100% disease-free rate in head and neck cancer patients after a median follow-up of 24.1 months.
• The Phase I trial data highlights the vaccine's strong immunogenicity, with immune responses targeting selected neoantigens observed in all patients.
• The ongoing trial has been expanded to a Phase I/II study to further evaluate TG4050's efficacy in preventing relapse in this high-risk patient population.
• TG4050 leverages Transgene's myvac® platform and NEC's AI to optimize antigen selection, offering a personalized approach to cancer treatment.
TG4050 Neoantigen Vaccine Shows Sustained Disease-Free Survival in Head and Neck Cancer Trial
• A Phase I trial of TG4050 in head and neck cancer showed that all patients treated with the vaccine after standard care remained disease-free after 24.1 months.
• The individualized immunotherapy induced specific and sustained immune responses against selected neoantigens in all treated patients, demonstrating strong immunogenicity.
• Based on these promising results, the trial has been expanded into a Phase I/II study, with the Phase II portion currently enrolling patients internationally.
• The neoantigen cancer vaccine TG4050 demonstrates potential to prevent relapse in patients with locally advanced resected head and neck squamous cell carcinoma (HNSCC).
LUMINOSITY Trial: Telisotuzumab Vedotin Shows Promising Patient-Reported Outcomes in c-Met+ NSCLC
• The LUMINOSITY trial evaluated telisotuzumab vedotin (Teliso-V) in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous non–small cell lung cancer (NSCLC).
• Patient-reported outcomes (PROs) from the trial showed improvements in key symptoms like dyspnea, cough, and chest pain, correlating with observed response rates.
• The analysis revealed that quality of life (QOL) and physical functioning were generally maintained during treatment with Teliso-V, with prolonged time to deterioration in QOL in responders.
• Peripheral neuropathy, mostly grade 1 and 2, was a noted adverse effect, but Teliso-V demonstrated a strong efficacy signal in late-line treatment, contributing to better QOL.
Valerio Therapeutics Expands Antibody Development Capabilities with Emglev Therapeutics Acquisition
• Valerio Therapeutics has acquired Emglev Therapeutics, gaining access to innovative single-domain antibody (sdAb) technology that enables fully human antibody development through in vitro processes.
• The acquisition, executed through Valerio's subsidiary Valour Bio, strengthens their therapeutic pipeline with applications in autoimmune diseases, inflammatory disorders, and cancer treatment modalities.
• Emglev's platform has demonstrated preclinical success with various therapeutic approaches, including CAR-T sdAb, BiTE sdAb, and sdAb-drug conjugates, promising accelerated development with reduced immunogenicity risks.
VESPER Trial: BaSq Subtype Linked to Poorer Outcomes in Bladder Cancer
• The VESPER trial's molecular subtyping analysis reveals the BaSq subtype (pure or mixed) is associated with decreased progression-free survival and overall survival in bladder cancer patients.
• Patients in the neoadjuvant setting who received dose-dense MVAC chemotherapy showed significantly higher three-year progression-free survival compared to those receiving gemcitabine and cisplatin.
• Extended follow-up of the VESPER trial demonstrated improved overall survival at 5 years in the dose-dense MVAC group versus the gemcitabine + cisplatin group within the neoadjuvant subgroup.
• Further research is needed to understand the biological bases for mixed tumors and to improve prognosis for BaSq subtype tumors.
Telisotuzumab Vedotin Improves Patient-Reported Outcomes in c-Met+ NSCLC
• The LUMINOSITY trial showed telisotuzumab vedotin (Teliso-V) yielded a 29% response rate in patients with c-Met-overexpressing, EGFR wild-type, nonsquamous NSCLC.
• Patient-reported outcomes from LUMINOSITY indicated improvements in key cancer-related symptoms like cough and chest pain with Teliso-V treatment.
• The trial also demonstrated that Teliso-V maintained quality of life and physical functioning, particularly in patients achieving disease control.
• Peripheral neuropathy, a notable side effect, was reported by patients, highlighting the need for proactive management in subsequent trials.
Advancements in NSCLC Treatment: Novel Immunotherapy Combinations and Perioperative Strategies Show Promise
• A phase 2 study (RELATIVITY-104) reveals that adding relatlimab to nivolumab and chemotherapy improves outcomes in advanced NSCLC with PD-L1 ≥ 1% and non-squamous histology.
• Perioperative nivolumab demonstrates a 40% reduction in disease recurrence or death compared to neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to patient-level data analysis.
• A phase 2 trial suggests aggressive local consolidative therapy (LCT) combined with systemic chemotherapy may extend survival in stage IV NSCLC with oligometastases.
Greenwich LifeSciences' Flamingo-01 Trial Expands into Europe and Broadens Patient Enrollment
• Greenwich LifeSciences' Flamingo-01 Phase III trial, evaluating GLSI-100 for breast cancer recurrence prevention, has been approved for expansion into Europe, including Spain, France, Germany, Italy, and Poland.
• The Flamingo-01 trial will activate 105 sites in Europe, with site initiation visits starting as early as March 4, 2024, aiming to enroll more patients and accelerate the study.
• The trial's steering committee has agreed to expand the third arm of the study to enroll up to 250 patients with non-HLA-A*02 types, potentially broadening the patient population who could benefit from GLSI-100.
• Greenwich LifeSciences is preparing for a BLA filing in the US, including commercial manufacturing data and study reports from prior clinical trials, marking progress toward potential commercialization of GLSI-100.
Tailored Axillary Surgery: A Novel Approach for Clinically Node-Positive Breast Cancer
The TAXIS trial explores the concept of tailored axillary surgery (TAS) for clinically node-positive breast cancer patients, aiming to reduce tumor load to a level manageable by radiotherapy, potentially avoiding the need for axillary lymph node dissection (ALND). This approach could significantly decrease surgery-related morbidity and improve quality of life, with disease-free survival as the primary endpoint.
© Copyright 2025. All Rights Reserved by MedPath